Vargha László et al. (szerk.): Beszámoló a Gyógyszeripari Kutató Intézet 10 éves működéséről 1950-1959 (Budapest, 1969)

Dr. Bagdy Dániel: Az elasztáz előállítása, tulajdonságai és gyógyászati felhasználása

содержащие антиэластазу, подавляют действие эластазы в большей мере чем нормальные контрольные сыворотки. В пределах известных концентраций эластаза обладает способностью свертывать полную кровь или плазму: такое действие основывается на том, что эластаза способна превратить протромбин в тромбин. Кроме этого, эластаза способна также и к свертыванию молока.

В ходе испытаний, направленных на терапевтическую применяемость вещества, было установлено, что при лечении нагноения легких и плевры эластаза обеспечивает отличные терапевтические результаты. Она обладает меньшим раздражающим действием чем стрептокиназа-стрептодорназа и трипсин, причем эффект проявляется быстрее. Кроме этого, эластаза с успехом применяется также и в первой фазе лечения кожных язв, для очищения пораженных и некротических тканей.

В результате вышесказанных исследований запас патентированных средств обогащается новым и оригинальным венгерским препаратом.

DÁNIEL BAGDY :

THE PRODUCTION, PROPERTIES AND THERAPEUTIC APPLICATION

OF ELASTASE

A new adsorption method has been developed for preparing elastase, discovered by Baló and Banga, which permits to obtain an enzyme preparation of high parity by an economic process. Investigations concerning the chemical, biological and pharmacological properties we found that 1. elastase is capable of dissolving also other proteins th&n elastin (e. g. prothrombin, fibrinogen, etc.) ; the elastolytic activity of the enzyme is diminished by iodination, desamination, treatment with formaldehyde, whereas the proteolytic activity decreases at the same time to a lesser extent. As shown by our experiments, the specific elastolytic, but nonspecific proteolytic activity of the elastase molecule cannot be ascribed to a common active centre ; the part responsible for the elastolytic activity is more sensitive to various agents. 2. Administered intravenously to cats, the enzyme causes hypotension. The hypotensive action is due chiefly to dilatation of the peripheral blood vessels and capillaries. The enzyme increases the amplitude of the frog’s heart, the tone of smooth muscle organs, and elicits specific uterine contractions in rats during the estral phase. The intravenous toxicity of the enzym preparations is in proportion to their elastolytic activity, this toxicity can be efficiently reduced by the use of antiphlogistic drugs and elastase inhibitors. On the other hand, elastase does not cause any tissular damage in intact mucous membrane, when administered topically. 3. The supposed role of elastase in the pathogeny of atherosclerosis could not be confirmed. It has been ascertained that the elastase-inhibiting action of normal blood serum can be ascribed, in the first place, to a macromolecular inhibitor, protein-type. The action of elastase is inhibited more effectively by rabbit immunsera containing antielastase than by normal sera. Within certain concentration limits elastase may coagulate whole blood or plasma ; its coagulating action is due to the fact that it converts prothrombin into thrombin. Elastase has also a rennet-activity. 4. Research concerning its therapeutic applications has furnished evidence of the highly favourable results ensured by elastase in the treatment of pulmonary and pleural suppurations. It is less irritating than streptokinase-streptodornase or trypsin, and its action manifest more promptly. Furthermore, it can be successfully employed also for the therapy of skin ulcers, in the first stage of treatment, for removing impaired and necrotic tissue.

162